Valion Bio, Inc.
VBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$154.13K
Close$
$5.36
370% upside
Current Fair Value
370% upsideUndervalued by 370% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $154,127.00 |
|---|---|
| Enterprise Value | $8.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.84 |
| Beta | 1.8 |
| Outstanding Shares | 135,199 |
Return
| Return on Equity | -232.50% |
|---|---|
| Return on Assets | -30.40% |
| Return on Invested Capital | -37.11% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.01 |
| Price to Sales | -0.57 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | -51.71 |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.24 |
| Debt to Equity | 2.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-10200.00
Average shareholder expectationRevenue Estimate
$460,000
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-408.00
Average shareholder expectationRevenue Estimate
$460,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Valion Bio, Inc.
52 employees
CEO: Michael R. Cavanaugh Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimo...